evidence and early-stage clinical studies point to a potential synergy between currently available immunotherapeutic agents and standard anticancer therapies such as radiation and chemotherapy. Several other…
nanotechnology provides numerous advantages in the treatment of chronic human diseases. Chemotherapeutic agents, biological agents, immunotherapeutic agents, and other exceptional uses of nanomedicine have been observed…
tested the bioactivity of GIFT4 as a potential immunotherapeutic agent against caner. We observed that GIFT4 directly elicits anti-tumor adaptive B-cell immune response and consequent T cell immunity ... anti-tumor…
Genetically engineered stem cells (GESTECs) producing suicide enzymes and immunotherapeutic agents along with their strong tumor tropism have a definite therapeutic potential in anticancer treatment. Suicide enzymes can…
that have been noted from CPB, the Objective Response Rate (ORR) of a single-agent CPB has been limited to 30% in most tumors. However, there is a subgroup ... high MSI would not do well with chemotherapy and they would…
advances in melanoma therapy over the past several years, with several molecularly targeted and immunotherapeutic agents recently FDA-approved for use the treatment of patients with metastatic disease. However with
understanding the mechanism of lipid antigen recognition and would aid in designing new immunotherapeutic agents to modulate immune responses in various clinical settings
Recently, there are a number of outstanding applications of the nanomedicine (chemotherapeutic agents, biological agents, immunotherapeutic agents etc.) in the treatment of various diseases. The current review, presents…
Recently, there are a number of outstanding applications of the nanomedicine (chemotherapeutic agents, biological agents, immunotherapeutic agents etc.) in the treatment of various diseases. The current review, presents…
myeloma) continued to lag far behind. On the other hand, humoral and cellular immunotherapeutic agents were quite successful in selected hematologic malignancies, albeit patients with Relapsed/Refractory (R/R) disease…
membrane. This antibody have demonstrated significant disease control rate of over 45% as single agent in the locally recurrent/metastatic disease setting. The combination of cetuximab with platinum-based ... rate of up…
have gained significant attention as promising approaches to improve the therapeutic outcome of anticancer agents. Lipid vesicular systems, including liposomes, niosomes, transferosomes, ethosomes, phytosomes, and…
genotypes that may no longer be controlled by an established active or passive immunotherapeutic protocol agent. Here we deal with molecular techniques to circumvent these obstacles
high degree of accuracy for diagnosis and when confirmed, be used as a therapeutic agent to target and destroy the malignancy. Antibodies for a large array of neoplasms ... failure the average improvement in survival is…
specific immune pathways with unprecedented precision. This review explores the mechanistic basis of novel immunotherapeutic agents, evaluates their clinical efficacy, and discusses future innovations such as…
enhance immune cell infiltration and activation. Recent clinical trials, particularly those involving novel immunotherapeutic agents and tumor vaccines, are examined to understand their efficacy and limitations. Our…
therapeutic potential of immune modulation in managing established cancers, discussing the efficacy of immunotherapeutic agents in clinical trials and their effects on tumor progression and patient outcomes
improve the efficacy of conventional and new medications, including natural products. Chemotherapeutic, biological, and immunotherapeutic agents are only a few of the many uses. A noteworthy feature is how nanomaterials
Mismatch Repair (dMMR) metastatic Colo Rectal Cancer (CRC), leading to FDA approval of several immunotherapeutic agents. Clinical trials have explored the use of immunotherapy in localized dMMR CRC, with promising
biology and genetic background of AML to discover effective target therapies and immunotherapeutic agents, particularly when intensifying the currently used conventional chemotherapies may not be possible without…
modify the immune response through cytokine production. When NK cells were utilised as immunotherapeutic agents and demonstrated safety and efficacy in the treatment of patients with advanced-stage leukaemia, this
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.